Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Aug;111(11):1429–1438. doi: 10.1289/ehp.6396

Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects.

Meei-Maan Wu 1, Hung-Yi Chiou 1, I-Ching Ho 1, Chien-Jen Chen 1, Te-Chang Lee 1
PMCID: PMC1241636  PMID: 12928151

Abstract

Long-term arsenic exposure is associated with an increased risk of vascular diseases including ischemic heart disease, cerebrovascular disease, and carotid atherosclerosis. The pathogenic mechanisms of arsenic atherogenicity are not completely clear. A fundamental role for inflammation in atherosclerosis and its complications has become appreciated recently. To investigate molecular targets of inflammatory pathway possibly involved in arsenic-associated atherosclerosis, we conducted an exploratory study using cDNA microarray and enzyme-linked immunosorbent assay to identify genes with differential expression in arsenic-exposed yet apparently healthy individuals. As an initial experiment, array hybridization was performed with mRNA isolated from activated lymphocytes of 24 study subjects with low (0-4.32 microg/L), intermediate (4.64-9.00 microg/L), and high (9.60-46.5 microg/L) levels of blood arsenic, with each group comprising eight age-, sex-, and smoking frequency-matched individuals. A total of 708 transcripts of known human genes were analyzed, and 62 transcripts (8.8%) showed significant differences in the intermediate or high-arsenic groups compared with the low-level arsenic group. Among the significantly altered genes, several cytokines and growth factors involving inflammation, including interleukin-1 beta, interleukin-6, chemokine C-C motif ligand 2/monocyte chemotactic protein-1 (CCL2/MCP1), chemokine C-X-C motif ligand 1/growth-related oncogene alpha, chemokine C-X-C motif ligand 2/growth-related oncogene beta, CD14 antigen, and matrix metalloproteinase 1 (interstitial collagenase) were upregulated in persons with increased arsenic exposure. Multivariate analyses on 64 study subjects of varying arsenic exposure levels showed that the association of CCL2/MCP1 plasma protein level with blood arsenic remained significant after adjustment for other risk factors of cardiovascular diseases. The results of this gene expression study indicate that the expression of inflammatory molecules may be increased in human subjects after prolonged exposure to arsenic, which might be a contributory factor to the high risk of atherosclerosis in arseniasis-endemic areas in Taiwan. Further multidisciplinary studies, including molecular epidemiologic investigations, are needed to elucidate the role of arsenic-associated inflammation in the development of atherosclerosis and subsequent cardiovascular disease.

Full Text

The Full Text of this article is available as a PDF (412.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagla P., Kaiser J. India's spreading health crisis draws global arsenic experts. Science. 1996 Oct 11;274(5285):174–175. doi: 10.1126/science.274.5285.174. [DOI] [PubMed] [Google Scholar]
  2. Barchowsky A., Dudek E. J., Treadwell M. D., Wetterhahn K. E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 1996;21(6):783–790. doi: 10.1016/0891-5849(96)00174-8. [DOI] [PubMed] [Google Scholar]
  3. Barchowsky A., Roussel R. R., Klei L. R., James P. E., Ganju N., Smith K. R., Dudek E. J. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65–75. doi: 10.1006/taap.1999.8723. [DOI] [PubMed] [Google Scholar]
  4. Bates M. N., Smith A. H., Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992 Mar 1;135(5):462–476. doi: 10.1093/oxfordjournals.aje.a116313. [DOI] [PubMed] [Google Scholar]
  5. Bendeck Michelle P. Matrix metalloproteinases: are they antiatherogenic but proaneurysmal? Circ Res. 2002 May 3;90(8):836–837. doi: 10.1161/01.res.0000018141.73992.41. [DOI] [PubMed] [Google Scholar]
  6. Bernstam L., Nriagu J. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev. 2000 Oct-Dec;3(4):293–322. doi: 10.1080/109374000436355. [DOI] [PubMed] [Google Scholar]
  7. Cavigelli M., Li W. W., Lin A., Su B., Yoshioka K., Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996 Nov 15;15(22):6269–6279. [PMC free article] [PubMed] [Google Scholar]
  8. Chen C. J., Chiou H. Y., Chiang M. H., Lin L. J., Tai T. Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504–510. doi: 10.1161/01.atv.16.4.504. [DOI] [PubMed] [Google Scholar]
  9. Chen C. J., Hsueh Y. M., Lai M. S., Shyu M. P., Chen S. Y., Wu M. M., Kuo T. L., Tai T. Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995 Jan;25(1):53–60. [PubMed] [Google Scholar]
  10. Chen C. J., Wu M. M., Lee S. S., Wang J. D., Cheng S. H., Wu H. Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct;8(5):452–460. doi: 10.1161/01.atv.8.5.452. [DOI] [PubMed] [Google Scholar]
  11. Chen H., Liu J., Merrick B. A., Waalkes M. P. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog. 2001 Feb;30(2):79–87. doi: 10.1002/1098-2744(200102)30:2<79::aid-mc1016>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  12. Chen J. J., Wu R., Yang P. C., Huang J. Y., Sher Y. P., Han M. H., Kao W. C., Lee P. J., Chiu T. F., Chang F. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics. 1998 Aug 1;51(3):313–324. doi: 10.1006/geno.1998.5354. [DOI] [PubMed] [Google Scholar]
  13. Chiou H. Y., Huang W. I., Su C. L., Chang S. F., Hsu Y. H., Chen C. J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997 Sep;28(9):1717–1723. doi: 10.1161/01.str.28.9.1717. [DOI] [PubMed] [Google Scholar]
  14. Chouchane S., Snow E. T. In vitro effect of arsenical compounds on glutathione-related enzymes. Chem Res Toxicol. 2001 May;14(5):517–522. doi: 10.1021/tx000123x. [DOI] [PubMed] [Google Scholar]
  15. DeKoter R. P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science. 2000 May 26;288(5470):1439–1441. doi: 10.1126/science.288.5470.1439. [DOI] [PubMed] [Google Scholar]
  16. Devitt A., Moffatt O. D., Raykundalia C., Capra J. D., Simmons D. L., Gregory C. D. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature. 1998 Apr 2;392(6675):505–509. doi: 10.1038/33169. [DOI] [PubMed] [Google Scholar]
  17. Dong Zigang. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 (Suppl 5):757–759. doi: 10.1289/ehp.02110s5757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Elbirt K. K., Bonkovsky H. L. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):438–447. [PubMed] [Google Scholar]
  19. Engel R. R., Hopenhayn-Rich C., Receveur O., Smith A. H. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev. 1994;16(2):184–209. doi: 10.1093/oxfordjournals.epirev.a036150. [DOI] [PubMed] [Google Scholar]
  20. Engelse M. A., Neele J. M., van Achterberg T. A., van Aken B. E., van Schaik R. H., Pannekoek H., de Vries C. J. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res. 1999 Nov 12;85(10):931–939. doi: 10.1161/01.res.85.10.931. [DOI] [PubMed] [Google Scholar]
  21. Everett A. D., Stoops T., McNamara C. A. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 2001 Jul 31;276(40):37564–37568. doi: 10.1074/jbc.M105109200. [DOI] [PubMed] [Google Scholar]
  22. Germolec D. R., Spalding J., Boorman G. A., Wilmer J. L., Yoshida T., Simeonova P. P., Bruccoleri A., Kayama F., Gaido K., Tennant R. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res. 1997 Jun;386(3):209–218. doi: 10.1016/s1383-5742(97)00006-9. [DOI] [PubMed] [Google Scholar]
  23. Germolec D. R., Spalding J., Yu H. S., Chen G. S., Simeonova P. P., Humble M. C., Bruccoleri A., Boorman G. A., Foley J. F., Yoshida T. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol. 1998 Dec;153(6):1775–1785. doi: 10.1016/S0002-9440(10)65692-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hampe A., Shamoon B. M., Gobet M., Sherr C. J., Galibert F. Nucleotide sequence and structural organization of the human FMS proto-oncogene. Oncogene Res. 1989;4(1):9–17. [PubMed] [Google Scholar]
  25. Hsueh Y. M., Wu W. L., Huang Y. L., Chiou H. Y., Tseng C. H., Chen C. J. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis. 1998 Dec;141(2):249–257. doi: 10.1016/s0021-9150(98)00178-6. [DOI] [PubMed] [Google Scholar]
  26. Huo Y., Weber C., Forlow S. B., Sperandio M., Thatte J., Mack M., Jung S., Littman D. R., Ley K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001 Nov;108(9):1307–1314. doi: 10.1172/JCI12877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kitchin K. T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001 May 1;172(3):249–261. doi: 10.1006/taap.2001.9157. [DOI] [PubMed] [Google Scholar]
  28. Klouche M., Rose-John S., Schmiedt W., Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation. 2000 Apr 18;101(15):1799–1805. doi: 10.1161/01.cir.101.15.1799. [DOI] [PubMed] [Google Scholar]
  29. Kokura Satoshi, Yoshida Norimasa, Yoshikawa Toshikazu. Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions. Free Radic Biol Med. 2002 Aug 15;33(4):427–432. doi: 10.1016/s0891-5849(02)00852-3. [DOI] [PubMed] [Google Scholar]
  30. Lee T. C., Ho I. C. Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect. 1994 Sep;102 (Suppl 3):101–105. doi: 10.1289/ehp.94102s3101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Li Muyao, Cai Jiu-Feng, Chiu Jen-Fu. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem. 2002;87(1):29–38. doi: 10.1002/jcb.10269. [DOI] [PubMed] [Google Scholar]
  32. Libby Peter. Inflammation in atherosclerosis. Nature. 2002 Dec 19;420(6917):868–874. doi: 10.1038/nature01323. [DOI] [PubMed] [Google Scholar]
  33. Libby Peter, Ridker Paul M., Maseri Attilio. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135–1143. doi: 10.1161/hc0902.104353. [DOI] [PubMed] [Google Scholar]
  34. Libermann T. A., Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990 May;10(5):2327–2334. doi: 10.1128/mcb.10.5.2327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Liu Y., Guyton K. Z., Gorospe M., Xu Q., Lee J. C., Holbrook N. J. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med. 1996;21(6):771–781. doi: 10.1016/0891-5849(96)00176-1. [DOI] [PubMed] [Google Scholar]
  36. Lu T., Liu J., LeCluyse E. L., Zhou Y. S., Cheng M. L., Waalkes M. P. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci. 2001 Jan;59(1):185–192. doi: 10.1093/toxsci/59.1.185. [DOI] [PubMed] [Google Scholar]
  37. Ludwig S., Hoffmeyer A., Goebeler M., Kilian K., Häfner H., Neufeld B., Han J., Rapp U. R. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem. 1998 Jan 23;273(4):1917–1922. doi: 10.1074/jbc.273.4.1917. [DOI] [PubMed] [Google Scholar]
  38. Mitchell Peter. Drug industry lobbies against European research-data directive. Lancet. 1997 May 10;349(9062):1378–1378. doi: 10.1016/S0140-6736(05)63228-X. [DOI] [PubMed] [Google Scholar]
  39. Morrison T. B., Weis J. J., Wittwer C. T. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques. 1998 Jun;24(6):954-8, 960, 962. [PubMed] [Google Scholar]
  40. Nakagawa Yoshihito, Akao Yukihiro, Morikawa Hiroshi, Hirata Ichiro, Katsu Kenichi, Naoe Tomoki, Ohishi Nobuko, Yagi Kunio. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci. 2002 Mar 29;70(19):2253–2269. doi: 10.1016/s0024-3205(01)01545-4. [DOI] [PubMed] [Google Scholar]
  41. Nathe Tyler J., Deou Jessie, Walsh Bethany, Bourns Brenda, Clowes Alexander W., Daum Günter. Interleukin-1beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1293–1298. doi: 10.1161/01.atv.0000023428.69244.49. [DOI] [PubMed] [Google Scholar]
  42. Nordstrom D. Kirk. Public health. Worldwide occurrences of arsenic in ground water. Science. 2002 Jun 21;296(5576):2143–2145. doi: 10.1126/science.1072375. [DOI] [PubMed] [Google Scholar]
  43. Rosenfeld Michael E. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):361–363. doi: 10.1161/hq0302.104847. [DOI] [PubMed] [Google Scholar]
  44. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
  45. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20;314(8):488–500. doi: 10.1056/NEJM198602203140806. [DOI] [PubMed] [Google Scholar]
  46. Roussel R. R., Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys. 2000 May 1;377(1):204–212. doi: 10.1006/abbi.2000.1770. [DOI] [PubMed] [Google Scholar]
  47. Schönbeck U., Mach F., Sukhova G. K., Murphy C., Bonnefoy J. Y., Fabunmi R. P., Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997 Sep;81(3):448–454. doi: 10.1161/01.res.81.3.448. [DOI] [PubMed] [Google Scholar]
  48. Shin William S., Szuba Andrzej, Rockson Stanley G. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002 Jan;160(1):91–102. doi: 10.1016/s0021-9150(01)00571-8. [DOI] [PubMed] [Google Scholar]
  49. Snow E. T. Metal carcinogenesis: mechanistic implications. Pharmacol Ther. 1992;53(1):31–65. doi: 10.1016/0163-7258(92)90043-y. [DOI] [PubMed] [Google Scholar]
  50. Swart Guido W. M. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002 Jun;81(6):313–321. doi: 10.1078/0171-9335-00256. [DOI] [PubMed] [Google Scholar]
  51. Theodosiou Aspasia, Ashworth Alan. Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene. 2002 Apr 4;21(15):2387–2397. doi: 10.1038/sj.onc.1205309. [DOI] [PubMed] [Google Scholar]
  52. Tseng C. H., Chong C. K., Chen C. J., Lin B. J., Tai T. Y. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Int J Microcirc Clin Exp. 1995 Jan-Feb;15(1):21–27. doi: 10.1159/000178945. [DOI] [PubMed] [Google Scholar]
  53. Tseng C. H., Chong C. K., Chen C. J., Tai T. Y. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis. 1996 Feb;120(1-2):125–133. doi: 10.1016/0021-9150(95)05693-9. [DOI] [PubMed] [Google Scholar]
  54. Tseng C. H., Tai T. Y., Chong C. K., Tseng C. P., Lai M. S., Lin B. J., Chiou H. Y., Hsueh Y. M., Hsu K. H., Chen C. J. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000 Sep;108(9):847–851. doi: 10.1289/ehp.00108847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Tseng W. P. Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 1977 Aug;19:109–119. doi: 10.1289/ehp.7719109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Venkataraman M., Westerman M. P. Susceptibility of human T cells, T-cell subsets, and B cells to cryopreservation. Cryobiology. 1986 Jun;23(3):199–208. doi: 10.1016/0011-2240(86)90045-3. [DOI] [PubMed] [Google Scholar]
  57. Verma Subodh, Li Shu-Hong, Badiwala Mitesh V., Weisel Richard D., Fedak Paul W. M., Li Ren-Ke, Dhillon Bikramjit, Mickle Donald A. G. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002 Apr 23;105(16):1890–1896. doi: 10.1161/01.cir.0000015126.83143.b4. [DOI] [PubMed] [Google Scholar]
  58. Wang Chih-Hao, Jeng Jiann-Shing, Yip Ping-Keung, Chen Chi-Ling, Hsu Lin-I, Hsueh Yu-Mei, Chiou Hung-Yi, Wu Meei-Mann, Chen Chien-Jen. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002 Apr 16;105(15):1804–1809. doi: 10.1161/01.cir.0000015862.64816.b2. [DOI] [PubMed] [Google Scholar]
  59. Wittwer C. T., Herrmann M. G., Moss A. A., Rasmussen R. P. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 1997 Jan;22(1):130-1, 134-8. doi: 10.2144/97221bi01. [DOI] [PubMed] [Google Scholar]
  60. Wolpe S. D., Sherry B., Juers D., Davatelis G., Yurt R. W., Cerami A. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A. 1989 Jan;86(2):612–616. doi: 10.1073/pnas.86.2.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wu M. M., Chiou H. Y., Wang T. W., Hsueh Y. M., Wang I. H., Chen C. J., Lee T. C. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect. 2001 Oct;109(10):1011–1017. doi: 10.1289/ehp.011091011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yih Ling-Huei, Peck Konan, Lee Te-Chang. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis. 2002 May;23(5):867–876. doi: 10.1093/carcin/23.5.867. [DOI] [PubMed] [Google Scholar]
  63. Zhao C. Q., Young M. R., Diwan B. A., Coogan T. P., Waalkes M. P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10907–10912. doi: 10.1073/pnas.94.20.10907. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES